Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| FOXO4-DRI | Ipamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly. | Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | No established timing protocol. | Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach. |
| Cycle Duration | Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established. | 12-24 week cycles with 4-8 week breaks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
FOXO4-DRI is a D-retro-inverso peptide that selectively targets the FOXO4-p53 protein-protein interaction in senescent cells. In senescence, FOXO4 binds p53's disordered transactivation domain (TAD2) in the nucleus, preventing p53 from translocating to mitochondria where it would trigger apoptosis. FOXO4-DRI competitively disrupts this interaction, causing nuclear exclusion of p53 and its redirection to mitochondria, selectively inducing apoptosis in senescent cells while sparing healthy cells. The D-retro-inverso configuration provides protease resistance.
Research indicates dosing remains experimental. Mouse studies used 5 mg/kg IV, three times weekly.
No established timing protocol.
Mouse studies used intermittent dosing (3x/week for several weeks). Human protocols not established.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as the first selective growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) agonist. Unlike other GHRPs, it selectively stimulates GH release without significantly affecting ACTH, cortisol, prolactin, or aldosterone — even at doses 200-fold above the ED50 for GH release. This selectivity profile is comparable to GHRH itself but operates through the distinct ghrelin receptor on pituitary somatotrophs.
Research indicates 200-300 mcg administered 1-3 times daily via subcutaneous injection.
Best administered at bedtime for synergy with natural GH peak. Also effective upon waking and post-workout. Always on empty stomach.
12-24 week cycles with 4-8 week breaks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →